119 related articles for article (PubMed ID: 25609135)
1. Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Toblli JE; Cao G; Angerosa M
Biometals; 2015 Apr; 28(2):279-92. PubMed ID: 25609135
[TBL] [Abstract][Full Text] [Related]
2. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
3. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and predictive hepatic gene expression of intravenous iron sucrose.
Elford P; Bouchard J; Jaillet L; Pearson N; Rogue A; Sabadie C; Forster R
J Pharmacol Toxicol Methods; 2013; 68(3):374-83. PubMed ID: 23624021
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation.
Toblli JE; Cao G; Rivas C; Giani JF; Dominici FP
Int J Cardiol; 2016 Jun; 212():84-91. PubMed ID: 27038710
[TBL] [Abstract][Full Text] [Related]
6. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
Stein J; Dignass A; Chow KU
Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
[TBL] [Abstract][Full Text] [Related]
7. Comparison of early gastrointestinal tract and liver toxicity of the originator iron polymaltose complex (IPC) and an IPC similar preparation in non-anemic rats.
Toblli JE; Cao G; Angerosa M
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):573-83. PubMed ID: 22578204
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(7):399-410. PubMed ID: 21899208
[TBL] [Abstract][Full Text] [Related]
9. The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.
Toblli JE; Cao G; Angerosa M
J Clin Diagn Res; 2015 Dec; 9(12):FF08-12. PubMed ID: 26816915
[TBL] [Abstract][Full Text] [Related]
10. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Praschberger M; Cornelius C; Schitegg M; Goldenberg H; Scheiber-Mojdehkar B; Sturm B
Pharm Dev Technol; 2015 Mar; 20(2):176-82. PubMed ID: 24219061
[TBL] [Abstract][Full Text] [Related]
12. New rat models of iron sucrose-induced iron overload.
Vu'o'ng LĂȘ B; Khorsi-Cauet H; Villegier AS; Bach V; Gay-QuĂ©heillard J
Exp Biol Med (Maywood); 2011 Jul; 236(7):790-9. PubMed ID: 21685238
[TBL] [Abstract][Full Text] [Related]
13. Iron sucrose: assessing the similarity between the originator drug and its intended copies.
Di Francesco T; Philipp E; Borchard G
Ann N Y Acad Sci; 2017 Nov; 1407(1):63-74. PubMed ID: 29168243
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations.
Span K; Pieters EHE; Brinks V; Hennink WE; Schellekens H
J Pharmacol Toxicol Methods; 2018; 91():7-17. PubMed ID: 29278742
[TBL] [Abstract][Full Text] [Related]
15. Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.
Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
Drug Des Devel Ther; 2017; 11():2251-2263. PubMed ID: 28814833
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous vitamin C on cytokine activation and oxidative stress in end-stage renal disease patients receiving intravenous iron sucrose.
Conner TA; McQuade C; Olp J; Pai AB
Biometals; 2012 Oct; 25(5):961-9. PubMed ID: 22706571
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients.
Lee ES; Park BR; Kim JS; Choi GY; Lee JJ; Lee IS
Curr Med Res Opin; 2013 Feb; 29(2):141-7. PubMed ID: 23252876
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of toxicity and oxidative stress induced by intravenous iron isomaltoside 1000 in a nonclinical model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Arzneimittelforschung; 2011; 61(10):553-65. PubMed ID: 22164963
[TBL] [Abstract][Full Text] [Related]
19. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.
Pai AB; Conner T; McQuade CR; Olp J; Hicks P
Biometals; 2011 Aug; 24(4):603-13. PubMed ID: 21229380
[TBL] [Abstract][Full Text] [Related]
20. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]